ESC 365 - The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials

ESC Professional Premium Access

The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials

Session: Current pharmacological treatments for pulmonary hypertension

Topic: Pulmonary Hypertension

Speaker: Mr H. Khasawneh (Irbid, JO)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Hasan Khasawneh

Irbid (Jordan)

0 follower

8 more presentations in this session

Effects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL).

Speaker: Doctor M. Waligora (Krakow, PL)

Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension

Speaker: Doctor M. Stracqualursi (Milan, IT)

Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study

Speaker: Doctor H. Tokgoz (Istanbul, TR)

Metoprolol therapy in patients with Eisenmenger syndrome (MINES) study. A single-centre, double-blinded, randomised, placebo-controlled trial

Speaker: Doctor A. Pius (New Delhi, IN)

Efficacy of specific drug class therapy in pulmonary arterial hypertension associated with HIV, portal hypertension or both: a single Center experience

Speaker: Doctor F. Cennerazzo (Bologna, IT)

Access the full session

Current pharmacological treatments for pulmonary hypertension

Speakers: Mr H. Khasawneh, Doctor M. Waligora, Doctor M. Stracqualursi, Doctor H. Tokgoz, Doctor A. Pius...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources